secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K/A
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001625297-25-000064
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Indivior estimates $105-130M restructuring charges; exits six non-US markets
----------------------------------------------------------------------------

- Total pre-tax restructuring charges estimated at $105-130M, with $65M recognized in Q3 2025.
- Plans to exit markets: UK, Ireland, Sweden, Israel, Finland, Italy under Action Agenda Phase I.
- Expects at least $150M annual operating expense savings starting in 2026.
- Cash portion of charges $73-92M; includes severance, real estate, asset impairments, contract terminations.
- Headcount reductions cost $33-37M; real estate consolidation $15-21M; asset impairments $21-27M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000162529725000064/0001625297-25-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000162529725000064/indv-20250826.htm
  HTML page:      https://secwatch.observer/filing/0001625297-25-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer